Stage iv lung cancer ajcc v8 Trials in Carterville, United States
Conditions / Stage iv lung cancer ajcc v8 / Carterville, United States
Clinical trials for Stage iv lung cancer ajcc v8 investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06096844 | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | RECRUITING | — |
| NCT06073431 | LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia | RECRUITING | — |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | COMPLETED | PHASE2 |
| NCT03971474 | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | COMPLETED | PHASE2 |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | TERMINATED | — |
| NCT04310007 | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | RECRUITING | — |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | COMPLETED | — |